# A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

> **NCT01726946** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 10 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** VX-135
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01726946
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01726946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01726946, "A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01726946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*